sTILs Warrant Research as Response Biomarker in Metastatic Breast Cancer

Video

Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Daniel G. Stover, MD, spoke with CancerNetwork® about findings from the phase 3 CALGB 40502 (Alliance) trial (NCT00785291). In particular, he discussed how immune activation measured by stromal tumor infiltrating lymphocytes (TILs) may correlate with responses to microtubule-targeting agents among patients with metastatic breast cancer.1

Stover, associate professor of medicine and director of Translational Breast Cancer Research at The Ohio State University Comprehensive Cancer Center, stated that results from the AURORA study may also suggest a relationship between stromal TILs and patient outcomes in the metastatic setting, especially in those with triple-negative breast cancer (TNBC).2 However, he emphasized that additional trials are necessary for validating this association in other settings.

Transcript:

We performed multivariable analyses with additional factors and stromal TILs continued [to] trend towards association with outcomes. But there are multiple factors that influence a patient's response to these targeted therapies. Stromal TILs as a marker of immune activation should be one biomarker that could be incorporated as we think about optimizing therapy for patients. The [benefit] of stromal TILs is that it's such an accessible biomarker easily enumerated off routine slides.

This study certainly warrants further validation among additional samples in the metastatic setting. As we saw from the AURORA study presented in the same session, there is evidence that stromal TILs may have an association with outcomes in the metastatic setting, particularly among [TNBCs]. But the next step, beyond validating this in additional settings or situations, is to design those trials that can impact therapy decisions based on the stromal TIL number.

References

  1. Stover DG, Salgado R, Savenkov O, et al. Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: post hoc analysis CALGB 40502 (Alliance). J Clin Oncol. 2023;41(suppl 16):1010. doi:10.1200/JCO.2023.41.16_suppl.1010
  2. Hilbers F, Venet D, Agostinetto E, et al. Characterization of the immune microenvironment in matched primary and metastatic breast cancer lesions from the AURORA study: BIG 14-01. J Clin Oncol. 2023;41(suppl 16):1009. doi:10.1200/JCO.2023.41.16_suppl.1009

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content